Home » BBIL to manufacture CoroFlu a vaccine to cure Covid19

BBIL to manufacture CoroFlu a vaccine to cure Covid19

by Raju Vernekar
0 comment 1 minutes read

IT News

Imphal, April 8

The Hyderabad basedBharat Biotech International Limited (BBIL)” a vaccine manufacturing company, has began working on the development and testing “CoroFlu”, a unique intranasal vaccine against “Covid-19”.

“CoroFlu” will be based on FluGen, USA’s flu vaccine known as “M2SR”, which is a self-limiting version of the influenza virus that induces an immune response against the flu. FluGen’s laboratory will insert gene sequences from SARS-CoV-2, the coronavirus that causes Covid-10, into M2SR so that the new vaccine will also induce immunity against the pathogen.  

BBIL’s Business Development Head Raches Ella, said that “ Bharat Biotech will manufacture the vaccine, conduct clinical trials, and prepare to produce almost 300 million (30 crore) dosages of vaccine for global distribution. Under the collaboration agreement, “FluGen”, USA  will transfer its existing manufacturing processes to Bharat Biotech to enable the vaccine for clinical trials. 

Refinement of the “CoroFlu” vaccine concept and testing in laboratory animal models at University of Wisconsin–Madison, USA, is expected to take 3-6 months. Bharat Biotech, will then begin production scale-up for safety and efficacy testing in humans. “CoroFlu” could be in human clinical trials by end of current year. 

You may also like

Leave a Comment


Imphal Times is a daily English newspaper published in Imphal and is registered with Registrar of the Newspapers for India with Regd. No MANENG/2013/51092


©2023 – All Right Reserved. Designed and Hosted by eManipur!

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.